Grifols Slows Alzheimer’s Progression With Plasmapheresis
Plasmapheresis with Grifols’ Albutein could provide a new treatment avenue for Alzheimer’s disease, but more data will be needed to convince.
You may also be interested in...
Top-line Phase III data for faricimab in age-related macular degeneration leave Roche poised to file the bi-specific antibody for retinal diseases, but again there is no advantage with the novel dual-acting product over Eylea.
Biohaven’s investigational glutamate modulator troriluzole did not improve symptoms in patients with mild-to-moderate disease, adding to the list of failures in Alzheimer’s disease, as well as for the product itself.
The two companies can now market their HER-2 targeting antibody-drug conjugate in its second tumor type as they look to expand beyond breast cancer.